Just very quickly but i think the title sums it all up.
While it does appear very impressive & there is great interest there based soley on the fact that they have already secured 4 of the worlds top 10 pharmaceutical companies in low end entry deals it all comes back to the thread title - that's why they have put ink to paper in the first place afterall - to find the answer.
At this point despite the encouraging statements released by management on succesful outcomes & objectives achieved money always speaks. If the science did answer the thread title convincingly then the company wouldn't be valued at $12M & at the other end of long drawn out deal negotiations based on $1-2M up front payments - they would be stitched alot faster with greater upfronts, likely pharma taking weighted investment in the company itself or just a straight out take over. While of course there would be some shareholders that would likely hold back but based on current market price they could make a move on the company for anywhere between $50-$100M and likely get hold of a large percentage of the securities ---- but they haven't.
PYC Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)